Association between CD16( ) monocytes in peripheral blood and clinical features and short-term therapeutic effects of polycystic ovary syndrome
Association between CD16( ) monocytes in peripheral blood and clinical features and short-term therapeutic effects of polycystic ovary syndrome
复制标题
外周血CD16(+)单核细胞与多囊卵巢综合征临床特征及近期疗效的关系
DOI:
10.1002/ijgo.12779
复制
发表时间:
2019
影响因子:
3.8
通讯作者:
Zhu Xiaoyong
中科院分区:
文献类型:
--
作者:
Tang Lingli;Ye Jiangfeng;Shi Yingli;Zhu Xiaoyong
ObjectiveTo evaluate the association between CD16++monocytes in peripheral blood and the clinical features and short‐term therapeutic effects of polycystic ovary syndrome (PCOS).MethodsThis prospective cross‐sectional study included women diagnosed with PCOS at a University Hospital in Shanghai, China, between June 4 and November 28, 2016. Patients received Diane‐35, metformin, or both combined for 3 months. We collected anthropometric measures and used flow cytometry to detect CD16++monocytes.ResultsThe final analysis included 70 patients: 18 in the Diane‐35 group, 30 in the metformin group, and 22 in the Diane‐35 plus metformin group. The control group comprised 60 women without PCOS. The proportion of CD16++monocytes was significantly higher in patients with PCOS than in those with no PCOS (16.05% vs 10.73%;P=0.001). The proportion differed significantly between patients with and those without hyperandrogenism (13.12% vs 17.30%;P=0.002) and showed moderate accuracy in diagnosing hyperandrogenism before treatment. We noted a decrease in monocytes post‐treatment in patients given metformin and Diane‐35 plus metformin.ConclusionsThe proportion of CD16++monocytes was most significantly associated with hyperandrogenism before treatment. Our findings suggest that the proportion of CD16++monocytes in peripheral blood might be related to the inflammatory condition of PCOS.